Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Price Target at $82.29

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received an average rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $82.2857.

TARS has been the subject of several analyst reports. Guggenheim increased their price objective on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Mizuho started coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price target on the stock. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Finally, Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price for the company.

Tarsus Pharmaceuticals Price Performance

Shares of TARS opened at $75.01 on Friday. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -46.30, a PEG ratio of 1.01 and a beta of 0.57. The firm’s fifty day simple moving average is $72.25 and its 200-day simple moving average is $68.35. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.73%. The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Equities analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider directly owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 8.97% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its position in Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after purchasing an additional 136,582 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new position in Tarsus Pharmaceuticals in the third quarter valued at $14,264,000. TFG Asset Management GP Ltd raised its holdings in shares of Tarsus Pharmaceuticals by 40.1% in the second quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after buying an additional 71,530 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at about $15,898,000. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Tarsus Pharmaceuticals during the second quarter worth about $227,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Management guided 2026 revenue to $670M–$700M and reiterated XDEMVY’s potential for $2B+ peak sales, a major growth catalyst that supports higher valuation and investor optimism. Tarsus expects $670M–$700M 2026 sales as XDEMVY eyes blockbuster $2B+ potential while pipeline advances
• Positive Sentiment: Q4/FY2025 topline strength: FY2025 revenue jumped ~150% to $451M, Q4 sales beat consensus ($151.7M vs ~$144.6M), and management forecasts high gross margins (~93%) — signals of rapid commercial traction for XDEMVY and margin leverage ahead. Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential
• Neutral Sentiment: Management provided detailed commentary on international rollout timing (China 2026, Europe 2027) and commercial planning on the earnings call; these expand the TAM but will take time to convert into near-term revenue. Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Company posted a formal press release and slide deck summarizing Q4 results and strategic milestones — useful for investors modeling rollout assumptions and margin expansion. Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
• Negative Sentiment: GAAP EPS missed by $0.01 (reported -$0.20 vs. consensus -$0.19) and the company remains unprofitable with negative net margin and ROE; management now expects profitability in 2027, which delays cash-flow conversion risk. Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.